Blue Star Foods Reports Strong 2nd Half 2022 Performance Operating Metrics at its RAS Salmon Division
06 mars 2023 08h30 HE
|
Blue Star Foods Corp.
Validates the Business Model to Expand Facility Miami, FL, March 06, 2023 (GLOBE NEWSWIRE) -- Blue Star Foods Corp., (“Blue Star,” the “Company,” “we,” “our” or “us”) (NASDAQ: BSFC), an integrated...
Revolution Medicines Announces Pricing of $300.0 Million Public Offering of Common Stock
02 mars 2023 21h15 HE
|
Revolution Medicines, Inc.
REWOOD CITY, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines Announces Commencement of Public Offering of Common Stock
01 mars 2023 16h17 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress
27 févr. 2023 16h05 HE
|
Revolution Medicines, Inc.
Early clinical data on RMC-6236 provided in support of RAS(ON) Inhibitor platform validation Additional data releases for RMC-6236 (RASMULTI) and RMC-6291 (KRASG12C) expected in 2023 RMC-9805...
Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates
27 févr. 2023 08h00 HE
|
Immuneering Corporation
CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an...
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023
21 févr. 2023 16h05 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers,...
Blue Star Foods Closes $1.8 Million Underwritten Public Offering of Common Stock
14 févr. 2023 09h45 HE
|
Blue Star Foods Corp.
MIAMI, FL, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Blue Star Foods Corp., (NASDAQ:BSFC) (the "Company" ), an integrated Environmental, Social, and Governance (ESG) sustainable seafood company with a focus...
Blue Star Foods Prices $1.8 Million Underwritten Public Offering of Common Stock
10 févr. 2023 09h46 HE
|
Blue Star Foods Corp.
MIAMI, FL, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Blue Star Foods Corp., (NASDAQ:BSFC) (the "Company" ), an integrated Environmental, Social, and Governance (ESG) sustainable seafood company with a focus...
Revolution Medicines to Participate in Upcoming Investor Conferences
02 févr. 2023 07h00 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Qualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to Stockholders
01 févr. 2023 09h05 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for...